Fibrin sealants used to stop bleeding in surgery are made from fibrinogen and thrombin, proteins usually extracted from donated blood plasma. Fibriant, a biotech company at the Leiden Bioscience Park, produces human fibrinogen and thrombin in Chinese hamster ovary cells instead, and develops RecoSeel, a fully recombinant fibrin sealant, as its lead product.
In December 2021 Fibriant announced up to €16.5 million from the EIC Accelerator. CORDIS records a €2,500,000 grant towards a €4.50 million project, RECOFIB, planned from April 2022 to December 2023 and terminated on 2 February 2024. No results are published, and the news section of Fibriant's website still leads with the 2021 award. Dutch register data compiled by North Data show the company active, with 2023 accounts filed in March 2025 and a patent filing in April 2025.
Company file
- Legal entity
- Fibriant B.V., KvK 60436344, Leiden, Netherlands
- CEO
- Jaap Koopman (as of 2021)
- Technology
- Recombinant human fibrinogen variants and thrombin from CHO cells
- Lead product
- RecoSeel fibrin sealant (in development)
- Pipeline
- Products against MRSA infections; OEM supply of proteins
- EIC project
- RECOFIB, 1 Apr 2022, terminated 2 Feb 2024
- EIC funding
- Blended finance
Where Fibriant Stands Today
Fibriant's website describes RecoSeel as its "lead product in development" and pipeline products against MRSA infections, and says it is exploring supplying recombinant fibrinogen and thrombin to other companies. The latest news item is the December 2021 EIC award. The register shows the company still active; its 2023 accounts were filed more than a year after the year ended, and a new patent application on fibrinogen as an adjuvant for antimicrobial therapy was filed in April 2025. We found no clinical trial, product approval or funding round.
The Technology: Clotting Proteins Without Blood
According to the CORDIS fact sheet, RECOFIB's platform produces "fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost" without blood plasma, with greater stability, "significantly higher purity (10-100X)" and better safety than plasma-derived proteins. Planned uses were surgical haemostats, coatings for implants against antibiotic-resistant bacterial biofilms, and supply to other manufacturers.
"Fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost."
RECOFIB project description, CORDISWhat the EIC Project Promised, and What CORDIS Shows
RECOFIB aimed at "a unique commercially viable recombinant manufacturing platform". CORDIS lists the project as terminated on 2 February 2024, after its planned end date, and publishes no results or reports. The reason for the termination and the amount paid are not public, and no EIC Fund investment has been announced.
- A scalable production platformUnknownNo results published.
- RecoSeel into the clinicNot shownNo trial found.
- EIC project completedMissedTerminated February 2024.
- A company that continuesPartialActive in register; 2025 patent filing.
What Has Happened Since the Award
The Money
The "up to €16.5 million" Fibriant announced would, under the EIC's blended finance, combine the €2.5 million grant with equity; we found no record that the equity was invested. Register-linked data also list a €145,500 COVID-19 support subsidy in 2020. Fibriant's accounts were not accessible for this article.
What cannot be checked
Why the EIC project was terminated, how much of the grant was paid, whether any EIC equity was invested, and how far RecoSeel has progressed are not public.
Why Europe Should Care
Fibrin sealants depend on donated plasma, and a recombinant alternative would remove that dependence. Fibriant said the EIC backed this idea with up to €16.5 million. Almost five years later, the public cannot tell what came of it.
What the project promised
A commercially viable recombinant platform for human fibrinogen and thrombin.
What the record shows
A terminated EU grant, no published results, and a company whose public news stops in 2021.
The Verdict
A big announcement, then silence
Fibriant announced up to €16.5 million from the EIC. The EU grant was terminated, no results were published, and the company has said nothing publicly since. The EU should explain what happened to this award.
Fibriant has not been asked for comment for this article. It is based entirely on company statements, EU project data and Dutch register information, linked throughout.
